Gemcitabine, oxaliplatin and weekly high-dose 5-FU as a 24-hr-infusion in chemonaive patients with advanced or metastatic carcinoma of the gallbladder: Preliminary results of a multicenter phase II-study
Abstract only 4129 Background: Combinations of gemcitabine (GEM)/5-FU, GEM/oxaliplatin (LOHP) or 5-FU/LOHP work synergistically in pancreatic and/or colorectal malignancies, and have non-overlapping safety profiles. This phase II-study was designed to evaluate the efficacy and safety of the triple c...
Saved in:
Published in | Journal of clinical oncology Vol. 24; no. 18_suppl; p. 4129 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
20.06.2006
|
Online Access | Get full text |
Cover
Loading…
Abstract | Abstract only
4129
Background: Combinations of gemcitabine (GEM)/5-FU, GEM/oxaliplatin (LOHP) or 5-FU/LOHP work synergistically in pancreatic and/or colorectal malignancies, and have non-overlapping safety profiles. This phase II-study was designed to evaluate the efficacy and safety of the triple combination GEM/LOHP/5-FU in patients (pts) with advanced or metastatic carcinoma of the gallbladder. Methods: One-stage, multicentre phase II study. Eligibility criteria: chemonaive pts with histologically proven advanced, recurrent or metastatic gallbladder carcinoma (ECOG 0–1; expected survival >3 months; measurable disease; adequate renal, hepatic and bone marrow function). According to the results of our previous phase I-study (Proc ASCO 2003, # 1298), pts were treated with GEM 900mg/m
2
as a 30-min infusion, followed by LOHP 65 mg/m
2
(2-hr infusion) after a 30 min rest and 5-FU 1500 mg/m
2
(24-hr-infusion) on d 1, 8, every 3 weeks. Planned sample size: 35 response evaluable patients. The primary endpoint was tumor response, secondary endpoints were toxicity, median survival, the one-year-survival rate, clinical benefit and quality of life. Results: At time of abstract submission, median follow-up of 35 enrolled pts is 9.8 months. Pt. characteristics: m/f: 11/24, median age 61 (range 42–81), ECOG 0/1: 24/11 (69/31%) pts, locally advanced/metastatic disease 1/32 (3/91%) pts. Analysis of tumor response is still pending. Grade III/IV (NCI-CTC) toxicities occurred in 36/3% of 191 cycles and were: leucopenia 3/1%, neutropenia 4/1%, thrombocytopenia 4/1%, anemia 2/0%, nausea 1/0%, sensory neuropathy 4/0%, asthenia 1/0%, elevated bilirubin 2/0%, AP 4/0%, or elevated SGOT/SGPT 1/0%, edema 1/0%, infection 1/0%, dyspnoe 1/1%. Median survival of all pts is 9.9 months (95% CI: 7.5–11.5), the one-year-survival-rate is 30 % (95% CI: 16–47). Conclusions: GEM/LOHP/5-FU combination therapy is tolerated well in patients with gallbladder cancer. The promising survival data has to be confirmed in a phase III study. (Supported by grants from Eli Lilly and Company, Indianapolis, IN, USA and Sanofi-Synthelabo, Paris, France).
[Table: see text] |
---|---|
AbstractList | Abstract only
4129
Background: Combinations of gemcitabine (GEM)/5-FU, GEM/oxaliplatin (LOHP) or 5-FU/LOHP work synergistically in pancreatic and/or colorectal malignancies, and have non-overlapping safety profiles. This phase II-study was designed to evaluate the efficacy and safety of the triple combination GEM/LOHP/5-FU in patients (pts) with advanced or metastatic carcinoma of the gallbladder. Methods: One-stage, multicentre phase II study. Eligibility criteria: chemonaive pts with histologically proven advanced, recurrent or metastatic gallbladder carcinoma (ECOG 0–1; expected survival >3 months; measurable disease; adequate renal, hepatic and bone marrow function). According to the results of our previous phase I-study (Proc ASCO 2003, # 1298), pts were treated with GEM 900mg/m
2
as a 30-min infusion, followed by LOHP 65 mg/m
2
(2-hr infusion) after a 30 min rest and 5-FU 1500 mg/m
2
(24-hr-infusion) on d 1, 8, every 3 weeks. Planned sample size: 35 response evaluable patients. The primary endpoint was tumor response, secondary endpoints were toxicity, median survival, the one-year-survival rate, clinical benefit and quality of life. Results: At time of abstract submission, median follow-up of 35 enrolled pts is 9.8 months. Pt. characteristics: m/f: 11/24, median age 61 (range 42–81), ECOG 0/1: 24/11 (69/31%) pts, locally advanced/metastatic disease 1/32 (3/91%) pts. Analysis of tumor response is still pending. Grade III/IV (NCI-CTC) toxicities occurred in 36/3% of 191 cycles and were: leucopenia 3/1%, neutropenia 4/1%, thrombocytopenia 4/1%, anemia 2/0%, nausea 1/0%, sensory neuropathy 4/0%, asthenia 1/0%, elevated bilirubin 2/0%, AP 4/0%, or elevated SGOT/SGPT 1/0%, edema 1/0%, infection 1/0%, dyspnoe 1/1%. Median survival of all pts is 9.9 months (95% CI: 7.5–11.5), the one-year-survival-rate is 30 % (95% CI: 16–47). Conclusions: GEM/LOHP/5-FU combination therapy is tolerated well in patients with gallbladder cancer. The promising survival data has to be confirmed in a phase III study. (Supported by grants from Eli Lilly and Company, Indianapolis, IN, USA and Sanofi-Synthelabo, Paris, France).
[Table: see text] |
Author | Kleber, G. Moehler, M. Buechner-Steudel, P. Kuss, O. Behrens, R. Schmalenberg, H. Wagner, A. D. Fleig, W. E. Hahnfeld, S. Wein, A. |
Author_xml | – sequence: 1 givenname: A. D. surname: Wagner fullname: Wagner, A. D. organization: Martin-Luther University, Halle/Saale, Germany; F. Schiller University, Jena, Germany; Johannes Gutenberg University, Mainz, Germany; Gastroenterology Practice, Halle/Saale, Germany; Oncology Practice, Jena, Germany; F. Alexander Universität, Erlangen, Germany – sequence: 2 givenname: P. surname: Buechner-Steudel fullname: Buechner-Steudel, P. organization: Martin-Luther University, Halle/Saale, Germany; F. Schiller University, Jena, Germany; Johannes Gutenberg University, Mainz, Germany; Gastroenterology Practice, Halle/Saale, Germany; Oncology Practice, Jena, Germany; F. Alexander Universität, Erlangen, Germany – sequence: 3 givenname: H. surname: Schmalenberg fullname: Schmalenberg, H. organization: Martin-Luther University, Halle/Saale, Germany; F. Schiller University, Jena, Germany; Johannes Gutenberg University, Mainz, Germany; Gastroenterology Practice, Halle/Saale, Germany; Oncology Practice, Jena, Germany; F. Alexander Universität, Erlangen, Germany – sequence: 4 givenname: M. surname: Moehler fullname: Moehler, M. organization: Martin-Luther University, Halle/Saale, Germany; F. Schiller University, Jena, Germany; Johannes Gutenberg University, Mainz, Germany; Gastroenterology Practice, Halle/Saale, Germany; Oncology Practice, Jena, Germany; F. Alexander Universität, Erlangen, Germany – sequence: 5 givenname: O. surname: Kuss fullname: Kuss, O. organization: Martin-Luther University, Halle/Saale, Germany; F. Schiller University, Jena, Germany; Johannes Gutenberg University, Mainz, Germany; Gastroenterology Practice, Halle/Saale, Germany; Oncology Practice, Jena, Germany; F. Alexander Universität, Erlangen, Germany – sequence: 6 givenname: R. surname: Behrens fullname: Behrens, R. organization: Martin-Luther University, Halle/Saale, Germany; F. Schiller University, Jena, Germany; Johannes Gutenberg University, Mainz, Germany; Gastroenterology Practice, Halle/Saale, Germany; Oncology Practice, Jena, Germany; F. Alexander Universität, Erlangen, Germany – sequence: 7 givenname: S. surname: Hahnfeld fullname: Hahnfeld, S. organization: Martin-Luther University, Halle/Saale, Germany; F. Schiller University, Jena, Germany; Johannes Gutenberg University, Mainz, Germany; Gastroenterology Practice, Halle/Saale, Germany; Oncology Practice, Jena, Germany; F. Alexander Universität, Erlangen, Germany – sequence: 8 givenname: G. surname: Kleber fullname: Kleber, G. organization: Martin-Luther University, Halle/Saale, Germany; F. Schiller University, Jena, Germany; Johannes Gutenberg University, Mainz, Germany; Gastroenterology Practice, Halle/Saale, Germany; Oncology Practice, Jena, Germany; F. Alexander Universität, Erlangen, Germany – sequence: 9 givenname: A. surname: Wein fullname: Wein, A. organization: Martin-Luther University, Halle/Saale, Germany; F. Schiller University, Jena, Germany; Johannes Gutenberg University, Mainz, Germany; Gastroenterology Practice, Halle/Saale, Germany; Oncology Practice, Jena, Germany; F. Alexander Universität, Erlangen, Germany – sequence: 10 givenname: W. E. surname: Fleig fullname: Fleig, W. E. organization: Martin-Luther University, Halle/Saale, Germany; F. Schiller University, Jena, Germany; Johannes Gutenberg University, Mainz, Germany; Gastroenterology Practice, Halle/Saale, Germany; Oncology Practice, Jena, Germany; F. Alexander Universität, Erlangen, Germany |
BookMark | eNo1kcFq3DAQhkVJoZu07zC9V65kW-tVbyU06UIgOTTQm5lIo1ipLBnJm2SfsS9VLW1P_w8z8zHwnbOzmCIx9lGKRrZCfH4yqam5bdq-kbuxHJYlNL1s9Ru2kaod-DAodcY2YuhaLnfdz3fsvJQnIWS_69SG_b6m2fgVH3ykT5BeMfgl4OojYLTwQvQrHGHyjxO3qRAofnUPWACh7fmUuY_uUHyKUA_MRHOK6J8JlkqguBZ48esEaJ8xGrKQMsy0Ylnr2IDBbHxMM0JysE4EjxjCQ0BrKX-Bu0zBzz5iPkKmcgiVVvcQ5lq9qXTKsExYn9rveVkP9vievXUYCn34lxfs_urbj8vv_Ob2en_59YYbKbaaS9NpNZDU2pLVHbl2INRm6HHoa5eOjFSCRCs1uZ6sQNeR3TotBSm11d0F03-5JqdSMrlxyX6uj45SjCcrY7UynqyMbT_-tzKerHR_AJMZiqc |
CitedBy_id | crossref_primary_10_1093_annonc_mdn375 |
ContentType | Journal Article |
DBID | AAYXX CITATION |
DOI | 10.1200/jco.2006.24.18_suppl.4129 |
DatabaseName | CrossRef |
DatabaseTitle | CrossRef |
DatabaseTitleList | CrossRef |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1527-7755 |
EndPage | 4129 |
ExternalDocumentID | 10_1200_jco_2006_24_18_suppl_4129 |
GroupedDBID | --- .55 .GJ 0R~ 18M 2WC 34G 39C 3O- 4.4 53G 5GY 5RE 8F7 8WZ A6W AARDX AAWTL AAYEP AAYOK AAYXX ABJNI ABOCM ACGFO ACGFS ACGUR ADBBV AEGXH AENEX AFFNX AI. AIAGR ALMA_UNASSIGNED_HOLDINGS ASPBG AVWKF AWKKM AZFZN BAWUL C45 CITATION CS3 DIK EBS EJD F5P F9R FBNNL FD8 GX1 H13 HZ~ IH2 KQ8 L7B LSO MJL N4W N9A O9- OK1 OVD OWW P2P QTD R1G RHI RLZ RUC SJN SV3 TEORI TR2 TWZ UDS VH1 VVN WH7 X7M YCJ YFH YQY ZGI |
ID | FETCH-LOGICAL-c1069-1c3957e199ded93ef27ea9c74a74f271fec150e0219ef4ed0af3ed6f910e55693 |
ISSN | 0732-183X |
IngestDate | Fri Aug 23 03:50:23 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 18_suppl |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c1069-1c3957e199ded93ef27ea9c74a74f271fec150e0219ef4ed0af3ed6f910e55693 |
PageCount | 1 |
ParticipantIDs | crossref_primary_10_1200_jco_2006_24_18_suppl_4129 |
PublicationCentury | 2000 |
PublicationDate | 2006-06-20 |
PublicationDateYYYYMMDD | 2006-06-20 |
PublicationDate_xml | – month: 06 year: 2006 text: 2006-06-20 day: 20 |
PublicationDecade | 2000 |
PublicationTitle | Journal of clinical oncology |
PublicationYear | 2006 |
SSID | ssj0014835 |
Score | 1.8497916 |
Snippet | Abstract only
4129
Background: Combinations of gemcitabine (GEM)/5-FU, GEM/oxaliplatin (LOHP) or 5-FU/LOHP work synergistically in pancreatic and/or colorectal... |
SourceID | crossref |
SourceType | Aggregation Database |
StartPage | 4129 |
Title | Gemcitabine, oxaliplatin and weekly high-dose 5-FU as a 24-hr-infusion in chemonaive patients with advanced or metastatic carcinoma of the gallbladder: Preliminary results of a multicenter phase II-study |
Volume | 24 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fb9MwELa2IU28IBggfusQaC-tS5O4ScPbxBgrqKjSWmlvkeM4tKhtprQVjH-Rf4q7OE6yDgTsJUqT9uTq7rPv7O_uGHutBEbGgRNjmBqGXPQTyePUc7iTaowWnD66ELTfMfzsn07Ex_Pe-c7uqwZrabOOO-rHb_NKbqJVfIZ6pSzZ_9BsJRQf4D3qF6-oYbz-k44_6IXC2D6emW3J7Ds61RdEbjMM429FtfwWVSTmCfHSe_xkQo1lZMsVfJpzHMNmVZIdUXk4bklEorLWqk18syyBLKd-05JSkGaKSlqr2TJbSMsyoCP8eC6LiiTeEXE75kXHsPyyhSH9Zm5II9JQGIkTqvPWxRQX0dZgwOsqt9cd5Sp5M1uqrUOAL2W6zlGnddypdhY2dFygc3621pvEsBBG1dszNV3goljx2k6rN8NM21bQw872bojP3W5j0gw8l-M0dW7Wt3JSdwOMIkw5YDvrm8xta939aEVNVBszuXDKnRh95eO1Fcctmml_VZk52HJFxwrr1CKaVb63Vt-KE0nRGIqIUBT1BvUjV0RWVESidtktNwh7tMNwPPhUHZWJvukia__4PntZjuvNH0fVcMIa3tT4LrtTaheOjE3fYzt6ecD2hyXR44AdjkxJ9cs2jOsMwVUbDmFUF1u_vM9-NjDQhgYCABEABgFQIQAIASBXIOEqAgB_UCMALAKAEAAWAZDlUCMAKgRAlgIiABoIeAsN-4fS_ul7Ehr2D4X9g7X_B2xy8n787pSXDUq4crp-yB1Fp9waZ7lEJ6GnUzfQMlSBkIHAe5zvFMZbGt3oUKdCJ12ZejrxU3TRda_nh95DtrfMlvoRAzcVqpuGwtNUIpTqEnpOimuv9JMk7sbOY-ZajUUXpg5N9FeLeXKTHz1lt2tgPWN763yjn6PjvY5fFIb3C1yz3ts |
link.rule.ids | 315,786,790,27957,27958 |
linkProvider | Flying Publisher |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Gemcitabine%2C+oxaliplatin+and+weekly+high-dose+5-FU+as+a+24-hr-infusion+in+chemonaive+patients+with+advanced+or+metastatic+carcinoma+of+the+gallbladder%3A+Preliminary+results+of+a+multicenter+phase+II-study&rft.jtitle=Journal+of+clinical+oncology&rft.au=Wagner%2C+A.+D.&rft.au=Buechner-Steudel%2C+P.&rft.au=Schmalenberg%2C+H.&rft.au=Moehler%2C+M.&rft.date=2006-06-20&rft.issn=0732-183X&rft.eissn=1527-7755&rft.volume=24&rft.issue=18_suppl&rft.spage=4129&rft.epage=4129&rft_id=info:doi/10.1200%2Fjco.2006.24.18_suppl.4129&rft.externalDBID=n%2Fa&rft.externalDocID=10_1200_jco_2006_24_18_suppl_4129 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0732-183X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0732-183X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0732-183X&client=summon |